Zenlabs Ethica Ltd (ZENLABS) is currently trading at 20.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zenlabs Ethica Limited is a leading pharmaceutical contract marketing and trading company in India, known for its diverse range of branded drugs. The company was launched in collaboration with Zenlabs Pharmaceutical Inc, Canada, and has a strong focus on quality and affordable drug distribution. In 2023, Zenlabs Ethica ventured into Neurology and Cytrics, reflecting its diversification and expansion into new therapeutic areas. It offers over 600 products across various therapeutic segments, showcasing its comprehensive market outreach and product variety. As a WHO GMP certified company, it upholds high-quality standards in manufacturing and distribution.

Over the past 52 weeks, Zenlabs Ethica Ltd has traded between a low of ₹18.00 and a high of ₹39.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zenlabs Ethica Ltd has a market capitalization of approximately 13.00. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zenlabs Ethica Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -7.08 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 13.00 Cr, Zenlabs Ethica Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zenlabs Ethica Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zenlabs Ethica Ltd is -7.08. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.